Seaport Therapeutics develops novel antidepressants and anxiolytics using its proprietary Glyph™ platform. This technology is designed to improve drug candidates by enabling oral bioavailability and reducing first-pass metabolism. The company focuses on creating treatments for neuropsychiatric disorders with enhanced safety profiles, minimizing side effects like hepatotoxicity.
Funding
$225M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GAFounders
Product
Problem
Current antidepressants and anxiolytics often suffer from poor oral bioavailability and significant first-pass metabolism, leading to reduced efficacy and increased side effects such as hepatotoxicity. This can result in suboptimal patient outcomes and adherence challenges in treating neuropsychiatric disorders.
Solution
Seaport Therapeutics is developing a new generation of antidepressants and anxiolytics leveraging its proprietary Glyph™ platform to enhance oral bioavailability and minimize first-pass metabolism. By optimizing drug absorption and reducing hepatic exposure, the Glyph™ platform aims to improve therapeutic efficacy, reduce side effects, and ultimately enhance patient outcomes in the treatment of neuropsychiatric disorders. The company focuses on clinically validated mechanisms of action to ensure a targeted and effective approach to addressing mental health challenges.
Target Audience
The primary target audience includes individuals suffering from neuropsychiatric disorders, as well as psychiatrists and other healthcare professionals seeking more effective and tolerable treatment options.
Features
- Glyph™ platform technology designed to enhance oral bioavailability of drug candidates.
- Reduced first-pass metabolism to minimize hepatotoxicity and other side effects.
- Focus on clinically validated mechanisms of action for targeted therapeutic effects.
- Pipeline of novel antidepressants and anxiolytics.